NCT04230109: An ongoing trial by Massachusetts General Hospital
This trial is ongoing. It must report results 3 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04230109 |
|---|---|
| Title | A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 14, 2020 |
| Completion date | Oct. 31, 2028 |
| Required reporting date | Oct. 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |